ArticleCancer immunology, immunotherapy : CII2013
Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.
Article in Cancer immunology, immunotherapy : CII, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- The polymeric nanovectors landscape for cancer immunotherapies towards advanced therapy medicinal products (ATMPs).Acta pharmaceutica Sinica. B · 2026Review
- Review
- IL-2 Free Expansion of T Cells with Immunofilaments.Advanced healthcare materials · 2026Article
- Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing.Frontiers in immunology · 2026Review
- Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies.Antibodies (Basel, Switzerland) · 2025Review
- CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- The value of nucleoporin 188 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to gastric cancer verification.Frontiers in immunology · 2025Article
- Antibody-targeted T cells and natural killer cells for cancer immunotherapy.Journal of nanobiotechnology · 2024Article
- Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.Medical oncology (Northwood, London, England) · 2024Review
- T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.ImmunoHorizons · 2024Article
- Article
- CAR-T cell manufacturing: Major process parameters and next-generation strategies.The Journal of experimental medicine · 2024Review
- Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells.Gene therapy · 2023Article
- CAR T Cell Therapy: A Versatile Living Drug.International journal of molecular sciences · 2023Review
- Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular function.Molecular therapy. Methods & clinical development · 2022Article
- Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages.Molecular therapy. Methods & clinical development · 2022Article
- CD81 costimulation skews CAR transduction toward naive T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The adoptive transfer of lymphocytes genetically engineered to express tumor-specific antigen receptors is a potent strategy to treat cancer patients. T lymphocyte subsets, such as naïve or central memory T cells, selected in vitro prior to genetic engineering have been extensively investigated in preclinical mouse models, where they demonstrated improved therapeutic efficacy. However, so far, this is challenging to realize in the clinical setting, since good manufacturing practices (GMP) procedures for complex cell sorting and genetic manipulation are limited. To be able to directly compare the immunological attributes and therapeutic efficacy of naïve (T(N)) and central memory (T(CM)) CD8(+) T cells, we investigated clinical-scale procedures for their parallel selection and in vitro manipulation. We also evaluated currently available GMP-grade reagents for stimulation of T cell subsets, including a new type of anti-CD3/anti-CD28 nanomatrix. An optimized protocol was established for the isolation of both CD8(+) T(N) cells (CD4(-)CD62L(+)CD45RA(+)) and CD8(+) T(CM) (CD4(-)CD62L(+)CD45RA(-)) from a single patient. The highly enriched T cell subsets can be efficiently transduced and expanded to large cell numbers, sufficient for clinical applications and equivalent to or better than current cell and gene therapy approaches with unselected lymphocyte populations. The GMP protocols for selection of T(N) and T(CM) we reported here will be the basis for clinical trials analyzing safety, in vivo persistence and clinical efficacy in cancer patients and will help to generate a more reliable and efficacious cellular product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.